TSX-002 will reinforce Aspen's pipeline, further bolstering its presence in a key therapeutic area for the Group. The registration of the product will allow Aspen the opportunity to develop the testosterone market in emerging markets.
Whenever we can, we tend to use debt to fund deals, as Aspen is very cash generative, so it doesn't make sense to issue equity. Over time, we can eliminate debt.